Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management

Clinical Colorectal Cancer

Volumn 12, Issue 2, 2013, Pages 86-94

  Cartwright, Thomas H ^a,b  

^a US Oncology Research Inc   (United States)

^b Ocala Oncology   (United States)

Author keywords

Adverse events; Aflibercept; Antiangiogenic therapy; Bevacizumab; Colorectal cancer; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; PLACENTAL GROWTH FACTOR; VASCULOTROPIN A; VASCULOTROPIN B;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIANGIOGENIC THERAPY; ARTHRALGIA; BLEEDING; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; COLORECTAL CANCER; COMPASSIONATE USE; CREATININE BLOOD LEVEL; CYTOTOXICITY; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HAND FOOT SYNDROME; HEADACHE; HEART ARREST; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; VEIN EMBOLISM; VENOUS THROMBOEMBOLISM; VOICE CHANGE; VOMITING; WEIGHT REDUCTION; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR B;

EID: 84876879157     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2012.12.001     Document Type: Review

References (47)

1. F. Fan, J.S. Wey, M.F. McCarty Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells Oncogene 24 2005 2647 2653 (Pubitemid 40593092)
2. A. Grothey, E. Galanis Targeting angiogenesis: progress with anti-VEGF treatment with large molecules Nat Rev Clin Oncol 6 2009 507 518
3. F. Zhang, Z. Tang, X. Hou VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis Proc Natl Acad Sci U S A 106 2009 6152 6157
4. E.U. Cidón The challenge of metastatic colorectal cancer Clin Med Insights Oncol 4 2010 55 60
5. H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
6. B.J. Giantonio, P.J. Catalano, N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 2007 1539 1544 (Pubitemid 46733080)
7. Z.Z. Guan, J.M. Xu, R.C. Luo Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial Chin J Cancer 30 2011 682 689
8. J. Holash, S. Davis, N. Papadopoulos VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A 99 2002 11393 11398 (Pubitemid 34920936)
9. N. Papadopoulos, J. Martin, Q. Ruan Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab Angiogenesis 15 2012 171 185
10. Zaltrap [Package insert] 2012 Regeneron Pharmaceuticals, Inc Bridgewater, NJ
11. Avastin [Package insert] 2011 Genentech Inc South San Francisco, CA
12. H.S. Hochster, L.L. Hart, R.K. Ramanathan Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study J Clin Oncol 26 2008 3523 3529
13. J.R. Hecht, E. Mitchell, T. Chidiac A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 2009 672 680
14. M. Kozloff, M.U. Yood, J. Berlin Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study Oncologist 14 2009 862 870
15. J.A. Meyerhardt, K. Stuart, C.S. Fuchs Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer Ann Oncol 18 2007 1185 1189 (Pubitemid 47244364)
16. E. Van Cutsem, F. Rivera, S. Berry Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study Ann Oncol 20 2009 1842 1847
17. L.B. Saltz, S. Clarke, E. Díaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
18. C.S. Fuchs, J. Marshall, E. Mitchell Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study J Clin Oncol 25 2007 4779 4786 (Pubitemid 350086481)
19. C.S. Fuchs, J. Marshall, J. Barrueco Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study J Clin Oncol 26 2008 689 690 (Pubitemid 351264373)
20. S. Kopetz, P.M. Hoff, J.S. Morris Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance J Clin Oncol 28 2010 453 459
21. J. Souglakos, N. Ziras, S. Kakolyris Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) Br J Cancer 106 2012 453 459
22. A. Sobrero, S. Ackland, S. Clarke Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer Oncology 77 2009 113 119
23. F. Kabbinavar, H.I. Hurwitz, L. Fehrenbacher Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 2003 60 65
24. F.F. Kabbinavar, J. Schulz, M. McCleod Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial J Clin Oncol 23 2005 3697 3705
25. D.J. Renouf, S. Welch, M.J. Moore A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer Cancer Chemother Pharmacol 69 2012 1339 1344
26. L.B. Saltz, H.J. Lenz, H.L. Kindler Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study J Clin Oncol 25 2007 4557 4561 (Pubitemid 350035312)
27. A. Grothey, M.M. Sugrue, D.M. Purdie Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) J Clin Oncol 26 2008 5326 5334
28. Y. Horita, Y. Yamada, K. Kato Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial Int J Clin Oncol 17 2012 604 609
29. B.J. Giantonio, D.E. Levy, P.J. O'Dwyer A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200 Ann Oncol 17 2006 1399 1403 (Pubitemid 44400378)
30. G. Masi, F. Loupakis, L. Salvatore Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial Lancet Oncol 11 2010 845 852
31. B.J. Giantonio, H.X. Chen, P.J. Catalano Bowel perforation and fistula formation in colorectal cancer patients treated on Eastern Cooperative Oncology Group (ECOG) studies E2200 and E3200 J Clin Oncol 22 suppl 2004 A3017
32. J. Bennouna, C. Borg, J.P. Delord Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study Clin Colorectal Cancer 11 2012 38 44
33. D. Cunningham, R.P. Wong, G. D'haens A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): final PFS results J Clin Oncol 26 suppl 2008 A4028
34. T. Moriwaki, H. Bando, A. Takashima Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study) Med Oncol 29 2012 2842 2848
35. H.X. Chen, M. Mooney, M. Boron Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center trial TRC-0301 J Clin Oncol 24 2006 3354 3360 (Pubitemid 46638889)
36. D. Arnold, T. Andre, J. Bennouna Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup study (TML study) J Clin Oncol 30 suppl 2012 abstract CRA3503
37. P. Tang, S.J. Cohen, G.A. Bjarnason Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): a PMH phase II consortium trial J Clin Oncol 26 suppl 2008 abstract 4027
38. E. Van Cutsem, J. Tabernero, R. Lakomy Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen J Clin Oncol 30 2012 3499 3506
39. C. Pericay, G. Folprecht, M. Saunders Phase 2 randomized, noncomparative, open-label study of aflibercept and modified FOLFOX6 in the first-line treatment of metastatic colorectal cancer (AFFIRM) Ann Oncol 23 suppl 4 2012 abstract O-0024
40. K. Jin, Y. Shen, K. He Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer? Clin Transl Oncol 12 2010 526 532
41. M.L. Maitland, G.L. Bakris, H.R. Black Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors J Natl Cancer Inst 102 2010 596 604
42. J. Yeh, D. Frieze, R. Martins Clinical utility of routine proteinuria evaluation in treatment decisions of patients receiving bevacizumab for metastatic solid tumors Ann Pharmacother 44 2010 1010 1015
43. Antiemesis National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology - v.1.2012 National Comprehensive Cancer Network [Web site] http://www.nccn.org/professionals/physician-gls/pdf/antiemesis.pdf Accessed: September 7, 2012
44. Myeloid growth factors National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology - v.1.2012 National Comprehensive Cancer Network [Web site] http://www.nccn.org/professionals/physician-gls/pdf/myeloid-growth. pdf Accessed: September 7, 2012
45. National Cancer Institute Gastrointestinal complications (PDQ) 2011. Diarrhea http://www.cancer.gov/cancertopics/pdq/supportivecare/ gastrointestinalcomplications/HealthProfessional/AllPages#5 Accessed: September 7, 2012
46. G. Reid, E. Gaudier, F. Guarner Responders and non-responders to probiotic interventions: how can we improve the odds? Gut Microbes 1 2010 200 204
47. M.S. Copur, A. Obermiller An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition Clin Colorectal Cancer 10 2011 151 156